Table 6.3.
Examples of viral vector candidate vaccines in various stages of clinical development
| Vector | Pathogen target | Manufacturer |
|---|---|---|
| Early-stage development (Phase I) | ||
| Adenovirus | HIV Ebola-Marburg HCV |
Crucell |
| Adenovirus | Pandemic influenza | Paxvax |
| Adenovirus | Pandemic influenza | Vaxin |
| Attenuated influenza virus | Influenza HIV TB |
Polymun Scientific |
| Human or bovine PIV3 | PIV3/RSV | Medimmune AstraZeneca |
| Recombinant modified vaccinia Ankara | Measles | Bavarian Nordic |
| Replication incompetent adenovector | HSV | GenVec |
| Replication incompetent adenovector | HCV | Okairos |
| Vaccinia virus | HCV | Transgene |
| Mid-stage development (Phase II) | ||
| Adenovirus | Malaria TB |
Crucell |
| Adenovirus | HIV | Paxvax |
| Adeno-associated virus | HIV | Targeted Genetics |
| rMVA | Cancer | Oxford Biomedica |
| rMVA | TB | Emergent Biosolutions |
| rMVA | Smallpox Cancer HIV |
Bavarian Nordic |
| Replication incompetent adenovector | HIV Malaria |
GenVec |
| Replication incompetent adenovector | Malaria | Okairos |
| rMVA | Cancer HPV |
Transgene/Novartis Transgene/Roche |
| Vaccinia and fowlpox | Cancer | Bavarian Nordic |
| Yellow fever virus | Dengue West Nile |
Sanofi Pasteur |
| Late-stage development (Phase III) | ||
| rMVA | Cancer | Oxford Biomedica |
| Canarypox virus | HIV | Sanofi Pasteur |
HIV, human immunodeficiency virus; HCV, hepatitis C virus; TB, tuberculosis; PIV3, human parainfluenza virus type 3; RSV, respiratory syncytial virus; HSV, herpes simplex virus; rMVA, modified vaccinia virus Ankara; HPV, human papillomavirus. Every effort has been made to verify the information in this table. The information included is not meant to be exhaustive but is intended to provide an overview of the subject matter.